$36.020
+1.697 (+4.71%)收盘时
COAG 同业对比
In the context of the broader market, COAG competes directly with industry leaders such as NUVB and NVAX. With a market capitalization of $1.68B, it holds a significant position in the sector. When comparing efficiency, COAG's gross margin of N/A stands against NUVB's 70.11% and NVAX's 78.93%. Such benchmarking helps identify whether Hemab Therapeutics Holdings Inc is trading at a premium or discount relative to its financial performance.
Hemab Therapeutics Holdings Inc 财务表现
Hemab has a current ratio of 35.85, indicating strong liquidity, but it has reported negative net income for the last four quarters, with Q2 2026 showing a loss of $24.15 million.
Financials
FY2026Q2
0.00
Total Revenue
FY2026Q2
YoY:
+62.42%
-26.08M
Operating Profit
FY2026Q2
YoY:
+97.80%
-24.15M
Net Income after Tax
FY2026Q2
YoY:
+85.71%
-0.52
EPS - Diluted
FY2026Q2
YoY:
+47.79%
-22.66M
Free Cash Flow
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。